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Abstract
A plug-based microfluidic approach was used to perform multiple agglutination assays in parallel
without cross-contamination and using only microliter volumes of blood. To perform agglutination
assays on-chip, a microfluidic device was designed to combine aqueous streams of antibody, buffer,
and red blood cells (RBCs) to form droplets 30–40 nL in volume surrounded by a fluorinated carrier
fluid. Using this approach, proof-of-concept ABO and D (Rh) blood typing and group A subtyping
were successfully performed by screening against multiple antigens without cross-contamination.
On-chip subtyping distinguished common A1 and A2 RBCs by using a lectinbased dilution assay.
This flexible platform was extended to differentiate rare, weakly agglutinating RBCs of A subtypes
by analyzing agglutination avidity as a function of shear rate. Quantitative analysis of changes in
contrast within plugs revealed subtleties in agglutination kinetics and enabled characterization of
agglutination of rare blood subtypes. Finally, this platform was used to detect bacteria, demonstrating
the potential usefulness of this assay in detecting sepsis and the potential for applications in
agglutination-based viral detection. The speed, control, and minimal sample consumption provided
by this technology present an advance for point of care applications, blood typing of newborns, and
general blood assays in small model organisms.
This paper reports a plug-based microfluidic approach to perform agglutination assays for ABO
and D (Rh factor) blood typing and group A subtyping without cross-contamination. This
technology also minimizes sample consumption, an important advance for point of care
applications, blood typing of newborns, and general blood assays utilizing mice and other
model organisms. When antigens on the surface of red blood cells (RBCs) are exposed to
antibodies for that antigen, agglutination, or clumping, of RBCs occurs. These clumps are also
referred to as agglutinins. Agglutination is utilized to determine a patient’s blood type by
indicating the presence of specific antigens on the patient’s RBCs. Solid-phase agglutination
gel tests are used for greater than 90% of all ABO and D blood typing in emergency rooms
and blood banks.1 The gel tests require microliters of sample, minutes to perform, and give an
automated optical readout of agglutination.2 In addition, disposable plastic cards for point of
care applications, microtiter plates, laminar microfluidics, and now molecular approaches to
analyze expression of blood group antigens are also used in simple ABO and D blood typing.
3-6 However, both gel-based and card agglutination assays are performed separately for each
blood sample, increasing both labor and sample consumption.
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In addition to the common ABO and D blood groups, type A blood is divided into subtypes
that have fewer A antigens per RBC. Rare subtypes A3, Ax, Am, and Ael often shown no visible
agglutination reaction with the anti-A.1 As a result, A subtypes have a greater potential for
being mistyped as O blood and causing a hemolytic transfusion reaction in a recipient upon
transfusion.7-10 Currently, subtyping is performed in a separate assay from initial ABO and
D typing by using a “test tube” method that requires milliliters of blood and 45 min to complete.
A gel-based method of subtyping by using lectins is not yet commercially available.
Here, we describe a plug-based microfluidic method for blood typing that can resolve ABO
and D (referred to as + or -) groups as well as subtle agglutination differences between A blood
group subtypes. This system utilizes segmented flow microfluidic technology to perform
individual agglutination assays in “plugs”, aqueous droplets surrounded by a fluorinated carrier
fluid and transported through microfluidic channels. Microfluidics has been used previously
to perform kinetic measurements and a number of assays, including determination of glucose
level in blood and activated partial thromboplastin time.11-13 Previously, we have developed
methods to eliminate cross-contamination between plugs by inserting gas or liquid spacers and
perform highthroughput reaction screening by using preformed arrays of reagents.14-21 These
advances enable this system to perform serial typing of multiple blood samples in the same
experiment. We validate this plug-based microfluidic system by performing agglutination
assays for ABO and D typing as proof of principle, A subtyping by using a lectin assay, binding
avidity assays to distinguish strong from weak A subtypes, and detecting bacteria. This flexible
microfluidic platform could be easily modified to perform continuous blood typing in blood
banks or point of care assays by using preformed antibody arrays.
EXPERIMENTAL SECION
Reagents and Materials
Reagents were used as received unless otherwise specified. Type A+ human RBCs stabilized
with citrate were purchased from Innovative Research (Novi, MI), and type A2B+ human RBCs
stabilized with citrate-phosphate-dextroseadenine were purchased from Research Blood
Components (Brighton, MA). Weakly agglutinating type A human RBCs were donated by the
University of Chicago Blood Bank. Antibody IgM serum for anti-A, anti-B, and monoclonal-
polyclonal blend anti-D (Rh factor) were obtained from Orthoclinical Diagnostics (Raritan,
NJ). The buffer 2-amino-2-(hydroxymethyl)propane-1,3-diol (TRIS) and lyophilized lectin
from Dolichous biflorus were purchased from Sigma (St. Louis, MO). Sodium chloride was
purchased from Fisher (Hampton, NH). Fluoroinert 3283 was purchased from 3 M (Diegrem,
Belgium), and surfactant 1H,1H,2H,2H-perfluoro-1-octanol (PFO) was purchased from
Aldrich (Milwaukee, WI). Teflon tubing with an inner diameter (i.d.) of 300 μm used to connect
syringes to microfluidics device was purchased from Weico (Edgewood, NY). Telfon tubing
(i.d. = 150 μm) used for formation of antibody arrays was purchased from Zeus (Orange-burg,
SC). All syringes and 26-gauge needles were from Hamilton (Reno, NV). The Staphylococcus
aureus bacteria strain was obtained from American Type Culture Collection 25923 (Manassas,
VA). The Staphslide latex test was purchased from Arlington Scientific (Springville, UT). The
Mueller Hinton Agar with 5% sheep’s blood was purchased from Fisher (Hampton, NH).
The TRIS buffer was prepared as a 300 OsM solution: 20 mM TRIS and 130 mM sodium
chloride and pH adjusted to 7.4 at 25 °C with hydrochloric acid. RBCs were diluted 1:3 v/v
with TRIS buffer. In all experiments, the fluorinated carrier fluid consisted of 1:10 v/v of PFO
to FC3283.
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Fabrication of Microfluidic Devices
All microfluidic devices were fabricated as described previously by a procedure known as rapid
prototyping in poly(dimethylsiloxane) (PDMS).22-24 The design for devices used in the assays
shown in Figures 1, 3, 4, and 513 and the design for the device for creating preformed arrays
in Figure 216 have been previously reported. Microchannels were made hydrophobic by using
a previously described silanization procedure.25
Imaging and Quantification of Agglutination Results
We evaluated the presence of agglutination by monitoring individual plugs for an increase in
contrast over time. To monitor the agglutination reaction within each plug, plugs were manually
imaged with Metamorph imaging software on a Leica DMI 6000 epifluorescence microscope
(Wetzler, Germany) at approximately 2, 6, and 12 cm from the junction of the microfluidic
device (x = 0 cm), where plugs containing reagents are formed and the reaction is initiated.
The reaction time, t, was obtained from total volumetric flow rate by using t = v/d, where v is
linear velocity of fluid flow from volumetric flow rate and channel cross-sectional area and
d is distance from the merging junction as described previously.20 Images of different plugs
were manually captured with Metamorph, and these images were manually analyzed by mean
and variance filters in ImageJ to quantify the presence and extent of agglutinins by contrast.
Briefly, images were assembled into a stack that contained all of the images taken at each time
point during a single assay. In all figures, N = 3 plugs, except Figure 4, where N = 2 plugs. The
value of N = 3 plugs was chosen to maintain consistency with Figure 2, where technical
limitations dictated the value of N. In Figure 4, the microscope viewing area is limited to N =
2 plugs. A threshold for minimal agglutinin pixel size was measured with a line scan to
determine the difference in resolution between agglutinins and nonagglutinated cells. Contrast
values below the threshold represent nonagglutinated RBCs and are not counted by ImageJ.
Individual plugs in the stack were selected and analyzed with a variance filter to measure the
contrast in brightness in each plug. This contrast analysis method examined changes in intensity
between pixels in a given plug over time, eliminating the need to consider changes in intensity
from plug to plug or from day to day. An increase in contrast within a plug over time indicated
the presence of agglutination, while a plug that remained at a constant contrast was not
agglutinated.
Experiments To Distinguish Blood Type A from Type B
The carrier fluid flow rate was 5.5 μL/min in the device. Streams of the three aqueous solutions
were merged to form plugs. The first aqueous stream consisted of undiluted antibody serum at
a flow rate of 0.75 μL/min in the device. In separate experiments, this antibody serum was
either anti-A or anti-B. The flow rate of the antibody serum was kept low to minimize reaction
between the antibody and RBCs before plug formation. The second aqueous stream consisted
of a solution of TRIS buffer at a flow rate of 4 μL/min in the device. This aqueous stream was
used to minimize the reaction between antibody and RBCs before plug formation. The third
aqueous stream consisted of RBCs diluted from 100% as received to 33% v/v with TRIS buffer
at a flow rate of 0.25 μL/min in the device. RBCs were further diluted to ∼2% v/v on-chip with
other aqueous components. The total flow rate in the device was 10.5 μL/min (aqueous and
carrier fluid). Plugs of 30–40 nL in volume with anti-A or anti-B, respectively, were imaged
by using Metamorph at four locations in the device, with the first three locations denoted as
t1, t2, and t3 in Figure 1A for type A RBCs. Because the antibody stream wets the walls of the
inlet channel in this device, the agglutination assays using anti-A and anti-B were performed
by using two different devices to avoid mixing of antibodies.
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Experiments To Perform ABO and D Blood Typing
Plugs were aspirated manually into Teflon tubing (i.d. = 150 μm) in the following sequence:
three plugs of anti-A, two plugs of TRIS buffer, three plugs of anti-B, two plugs of TRIS buffer,
three plugs of anti-D, and two plugs of TRIS buffer. Air spacers were included between aqueous
plugs as illustrated in Figure 2A. The approximate volume of each plug in the array was 15–
20 nL. The array was then connected to the device illustrated in Figure 2B with capillary wax.
RBCs at a flow rate of 0.5 μL/min through a hydrophilic capillary were injected into aqueous
droplets also at a flow rate of 0.5 μL/min, diluting type A+ RBCs on-chip to a final concentration
of 1.5% v/v.
Experiments To Perform Subtyping of Type A Blood
Using the device illustrated in Figure 3A, aqueous streams of lectin, TRIS buffer, and RBCs
were merged to form plugs, and the resulting ∼40-nL plugs were monitored at five different
time points, t1—t5 illustrated in Figure 4A. We performed this assay with both A2B+ RBCs
and A+ RBCs at both high and low concentrations of lectin. In all trials, the flow rate of RBCs
was kept constant at 0.5 μL/min, and the final on-chip concentration of RBCs was 6% v/v. For
assays at low lectin concentration, flow rates of 0.25 μL/min for lectin and 2 μL/min for buffer
were used to dilute lectin from 1 to 0.09 mg/mL. Lower overall flow rates resulted in longer
assay times of ∼100 s. For assays at high lectin concentration, flow rates were 2 μL/min for
lectin and 0.25 μL/min for buffer to dilute lectin from 1 to 0.72 mg/mL. We also performed a
control experiment with two different type B RBCs (gift from University of Chicago Blood
Bank). Conditions for the control experiment were the same as those experiments using type
A RBCs.
Experiments To Resolve Weak Subtypes of Type A Blood by Using Shear
For these experiments, the device design illustrated in Figure 3A was modified to include
bumps on the walls of the winding channel to facilitate mixing and more uniform shear rate
within plugs.26 Plugs were formed by merging aqueous streams of anti-A, TRIS buffer, and
type A RBCs. Flow rates were 0.375 μL/min for anti-A, 1.0 or 1.5 μL/min for TRIS buffer,
0.25 μL/min for type A RBCs, and 4 μL/min for carrier fluid. When using strongly agglutinating
type A RBCs, the flow rate of the buffer was adjusted to 1.0 or 1.5 μL/min to minimize
agglutination at the merging junction. Shear rate was determined by dividing the total
volumetric flow rate by the product of the cross-sectional area and the diameter of the
microfluidic channel. Cross sections were measured with a Leica MZ 125 stereoscope at 6.3×
magnification. Shear rates given here are an approximation of the average shear experienced
by a plug. After plugs filled ∼32 mm of the device, the flow of all streams was stopped to
reduce the shear rate to 0 s-1, and plugs were observed for agglutination. Next, the flow rate
of the carrier fluid was increased to 250 μL/min to test the influence of shear rate on agglutinated
RBCs, and images were captured at 5× magnification. To distinguish agglutination of type O
RBCs from that of weakly agglutinating type A RBCs, a control experiment using type O+
RBCs (Innovative Research) was performed by using the same procedure as that described
above with the following exceptions. For type O+ RBCs, fluid flow rates for all reagents,
including carrier fluid, were resumed at initial conditions after the ∼10-min observation period
to show that agglutinins possess no binding avidity. This control experiment for type O RBCs
was compared to a control experiment with the weakly agglutinating type A RBCs where flow
rate of the carrier fluid was resumed after ∼10 min at a flow rate of 25 μL/min.
Experiments To Detect Bacteria
In these experiments, the same device design was used as that illustrated in Figure 1A, shown
again in Figure 5A. Plugs were formed by merging aqueous streams of antibody-coated latex
beads at a flow rate of 0.25 μL/min, TRIS buffer at a flow rate of 0.25 μL/min, and bacteria at
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a flow rate of 0.5 μL/min. The bacteria used in these experiments was S. aureus, a common
pathogenic bacteria, which was suspended in TRIS buffer at a concentration of ∼ 1 × 108
colony forming units (cfu)/mL. The concentration of bacteria used in these proof-of-concept
experiments may not be applicable in a clinical setting. Bacteria were grown overnight on 5%
sheep’s blood agar plates. Plug size was ∼45 nL for bacteria assays. Plugs were monitored for
agglutination at two time points, t1 and t2, as illustrated in Figure 5A.
RESULTS AND DISCUSSION
To perform agglutination assays on-chip, we designed a microfluidic device that combines
aqueous streams of antibody, buffer, and RBCs to form plugs of ∼40 nL in volume surrounded
by a fluorinated carrier fluid. All devices were fabricated from PDMS as previously described.
22,23 The ratio of aqueous solutions in the plugs was controlled by adjusting the flow rates of
the three aqueous streams. By controlling the concentration of each reagent in a plug, reagents
can be diluted on-chip, and multiple reaction conditions can be screened in the same
experiment.14,19 To achieve assay times comparable to gel-based agglutination assays, a
winding region was included immediately downstream of the merging junction to promote
rapid mixing of reagents by chaotic advection.19,20 Because the effectiveness of chaotic
mixing is only weakly dependent on the diffusivity of the species being mixed, this method
will be applicable to a wide range of species.19,20 The rate of mixing was controlled by flow
rate of the fluorinated carrier fluid.27 After mixing, plugs of antibody and RBCs were
monitored for agglutination at points downstream of the winding region.
A simplified agglutination assay demonstrated that this plug-based microfluidic system can
distinguish type A RBCs from type B RBCs. Solutions were delivered to the device as
illustrated in Figure 1A with pressure-driven flow, and plugs were imaged at approximately 2,
6, 10, and 12 cm from the merging junction. The first three time points, t1-t3, are shown in
Figure 1B and 1C. Assays utilizing anti-A and anti-B were performed in two separate
experiments with two different devices to avoid mixing of antibodies. When type A RBCs
were exposed to anti-A (Figure 1B; Figure 1D, blue squares), agglutination occurred, indicated
by an increase in contrast in plugs over time. Visually, agglutination of type A blood appeared
complete after 46 s (Figure 1B), and quantitative image analysis confirmed that agglutination
was complete in 28 s (Figure 1D). On the other hand, when type A RBCs were exposed to anti-
B, no agglutination was observed, and the contrast within plugs did not change (Figure 1C;
Figure 1D, red circles). Differences in the size of plugs between Figure 1B (30 nL) and C (40
nL) did not affect analysis of agglutination by the imaging software.
To enable screening of multiple antigens against a single blood sample without cross-
contamination, we used three-phase liquid—liquid—gas flow. Preformed arrays of antibody
plugs (Figure 2A) were generated by alternately aspirating plugs of antibody, air, and buffer
by using previously described methods.14-17 In the preformed arrays, buffer and air plugs
were placed between aqueous plugs16 to avoid cross-contamination of RBCs, agglutinins, or
antibodies between plugs. To generate a preformed array of antibodies on-chip, reagent plugs
could be separated by a third immiscible liquid as previously described.21 Preformed antibody
arrays can be generated in advance of the agglutination assay, providing reduced assay time
and the potential for point of care testing. The antibody plugs in a preformed array were merged
with RBCs (Figure 2B), and the resulting plugs were flowed through a winding region to
facilitate mixing. Plugs were monitored as described above. We confirmed consistent loading
of RBCs into plugs by comparing the size of plugs before and after merging with RBCs. When
type A+ RBCs were merged with plugs of the preformed antibody array, agglutination only
occurred in plugs containing anti-A or anti-D, but not in plugs containing anti-B (Figure 2C).
Therefore, this assay correctly typed the sample RBCs as type A+, providing proof of principle
for this plug-based microfluidic method of blood typing. Of the plugs tested during this assay
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(n = 9), no false-positive results were observed, indicating that no cross-contamination between
antibody plugs occurred. The previously described hybrid method17 could be used to
quantitatively screen for cross-contamination. Here, the flow rates were ∼5 times slower than
those used in the experiment described in Figure 1, and the total analysis time was less than 5
min.
To demonstrate the applicability of this technology to resolve common blood subtypes, we
performed on-chip subtyping of type A RBCs by using a well-established dilution assay with
lectin from D. biflorus (lectin DB).1 Subtype A1 RBCs have been shown to agglutinate in the
presence of lectin DB indifferent of lectin DB concentration, while subtype A2 RBCs are known
to agglutinate only in the presence of a high concentration of lectin DB.1 This selective
agglutination is believed to be due to the location of sugar groups on subtypes A1 and A2 RBCs
that bind lectin DB. Some B blood types have been reported to agglutinate in response to lectin
DB.28 As a control, we also tested two samples of type B RBCs and found that they did not
agglutinate in the presence of lectin DB. However, more extensive control testing would be
necessary before application in a clinical setting. In this microfluidic system that enables
multiple typing reactions simultaneously, this possibility of mistyping can be reduced by
specifically testing for type B RBCs before subtyping (Figure 2).
First, we performed a control assay to demonstrate that subtype A2 RBCs agglutinated in the
presence of lectin DB in the expected concentration-dependent manor. Here, we used type
A2B+ RBCs, and the lectin DB is sensitive to the A2 antigens. Plugs were formed as illustrated
in Figure 3A and monitored at five different time points, t1—t5. The concentration of lectin
DB was varied by changing the relative flow rates of buffer and lectin streams. As expected,
subtype A2B+ RBCs agglutinated in the presence of a high concentration of lectin DB (0.72
mg/mL) (Figure 3C; Figure 3E, blue hollow circles) but not in the presence of a low
concentration of lectin DB (0.09 mg/mL) (Figure 3B, Figure 3E, red solid circles). RBC density
in Figure 3B appears higher than in Figure 1B and C, because final on-chip concentration of
RBCs was two times greater in this experiment. After ∼7 s, agglutination of subtype A2B+
appears to be complete (Figure 3E, blue hollow circles).
Next, we performed the same agglutination assay described above using type A+ RBCs of an
unknown subtype. Agglutination of unknown samples of type A+ RBCs did not display
dependence on the concentration of lectin DB (Figure 3D; Figure 3F) when compared to
subtype A2B+ RBCs (Figure 3E). Agglutination of type A+ RBCs in the presence of lectin DB
at both high and low concentrations (Figure 3D; Figure 3F) indicates that these RBCs are
subtype A+1. Independent subtyping by using lectin DB-based tube assays by the American
Red Cross (Detroit, MI) and the Blood Bank at the University of Chicago Hospital confirmed
that these RBCs were subtype A+1.
In addition, these results indicate that subtypes A1 and A2 can be distinguished in as little as
100 s by using this plug-based microfluidic assay, an improvement over the 45 min required
for standard tube assays. The kinetics of agglutination for subtype A+1 RBCs were different
between low and high concentrations of lectin DB, exhibiting a slight increase in contrast within
each plug throughout the duration of the experiment for study at low concentration (Figure 3F,
black solid squares). Quantitative analysis by contrast suggests that subtleties in agglutination
can be resolved by using in plug-based subtyping. Therefore, this method may be extended to
resolve rare weakly agglutinating subtypes of the A or other blood groups in binding avidity
studies.
This plug-based microfluidic platform also provides an effective means of comparing relative
binding avidity by exposing RBCs to controlled shear rates, a method that can be utilized to
resolve less common, weakly agglutinating subtypes of group A RBCs. Binding avidity is
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correlated with the agglutination response in RBCs. The lectin DB-based dilution assay can
easily distinguish common subtypes A1 and A2 with strong binding avidity. However, subtypes
with weak binding avidity, including Ax,Ael, and Am, display weak or no agglutination when
exposed to lectin DB and therefore cannot be distinguished with the lectin DB dilution assay.
To investigate the influence of shear rate on the agglutination of RBCs with strong and weak
binding avidity, type A RBCs (Figure 4B) and weakly agglutinating type A RBCs of an
unknown subtype (Figure 4C) were exposed to anti-A and various flow rates of carrier fluid
in a microfluidic device to expose RBCs to various shear rates. The shear rate was controlled
by the flow rate of the carrier fluid and the geometry of the device. Shear rate was estimated
by dividing the linear, overall flow rate by the diameter of the channel to give an approximation
of the average shear rate in a plug.29,30 Plugs were formed by merging anti-A, buffer, and
RBCs in the device illustrated in Figure 4A. Here, a winding, bumpy channel was included in
the device design to facilitate better mixing and more uniform shear rate.26 While shear is not
uniform inside a moving plug, we believe RBCs in a plug can be assumed to experience average
shear when chaotic mixing is sufficiently rapid on the time scale of binding and unbinding to
rapidly transport the cells through the regions of higher and lower shear.
At the time of plug formation, the shear rate was 13 s-1. At this shear rate, type A RBCs with
strong binding avidity agglutinated within 8.9 s (Figure 4B, t1), while type A RBCs with weak
binding avidity did not agglutinate after 130 s (Figure 4C, t5). A lack of agglutination at this
shear rate would also likely be observed for type O RBCs. Next, the shear rate was reduced to
0 s-1 by stopping all flow rates, and type A RBCs with strong binding avidity remained
agglutinated as expected (Figure 4D), while type A RBCs with weak binding avidity formed
agglutinins (Figure 4F). These results indicate that a low shear rate of 13 s-1 hinders the
agglutination of RBCs with weak binding avidity. In addition, type A RBCs with weak binding
avidity require a considerably longer time, ∼10 min, to agglutinate in the absence of shear than
type A RBCs with strong binding avidity.
Then, the shear rate was increased from 0 to 530 s-1, and agglutinins of type A RBCs with
weak binding avidity broke up (Figure 4G). However, agglutinins of type A RBCs with strong
binding avidity remained agglutinated (Figure 4E). In ∼10% of the plugs of type A RBCs with
strong binding avidity (representative data in Figure 4E), small fragments of the agglutinin
broke away within 10 s at a shear rate of 530 s-1 (data not shown). Our results are consistent
with viscometer reports for reversing agglutination, where a shear rate of 600 s-1 breaks up
agglutinins.31 Contrast analysis shows that shear has little influence on agglutination of type
A RBCs with strong binding avidity (Figure 4H), while shear inhibits the agglutination of type
A RBCs with weak binding avidity, illustrated by spike in contrast within plugs of RBCs with
weak binding avidity at a shear rate of 0 s-1 in Figure 4I.
Preliminary results demonstrate that this assay is also capable of distinguishing weakly
agglutinating type A RBCs from type O RBCs by using shear. A traditional agglutination assay
utilizing anti-A or the lectin DB assay may not be effective in distinguishing weakly
agglutinating RBCs from type O RBCs, because both types of RBCs do not show an obvious
agglutination response to anti-A. However, the binding avidity of these types of RBCs differs
—weakly agglutinating type A RBCs with only a few A antigens will have a stronger binding
avidity to anti-A than type O RBCs that lack A group antigens completely. We performed the
same experiment described above using type O RBCs instead of weakly agglutinating type A
RBCs. Type O RBCs did not agglutinate when exposed to an initial shear rate of 10 s-1. Similar
to weakly agglutinating type A RBCs, type O RBCs agglutinated when shear was reduced to
0 s-1 for ∼10 min. However, agglutinins of type O RBCs broke up when flow was restored to
the initial flow rate of 10 s-1. In contrast, agglutinins of weakly agglutinating type A RBCs
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persisted at shear rates exceeding 52 s-1 (data not shown), indicating that weakly agglutinating
type A RBCs possess some unknown number of A antigens on their surface.
To illustrate the applicability of this technology beyond blood typing and subtyping, we
performed an agglutination assay to detect bacteria. The bacteria used here was S. aureus at a
concentration of ∼1 × 108 cfu/mL, and latex beads coated with antibody were used instead of
RBCs. Plugs were formed as illustrated in Figure 5A, and agglutination was monitored at four
time points. Agglutination in the presence of bacteria was visible 20 s after merging (Figure
5B, t1), and agglutinins were obvious after 150 s (Figure 5B, t2). This rapid increase in contrast
in plugs with bacteria over the 150-s observation period (Figure 5D, red squares) can likely be
attributed to the kinetics of the antibody—bacteria interaction. In the absence of bacteria,
contrast in plugs increases minimally over time (Figure 5C; Figure 5D, blue circles), possibly
due to nonspecific aggregation or sedimentation of latex particles.
CONCLUSIONS
In this paper, we presented a plug-based microfluidic system as proof of concept to perform
ABO and D blood typing and subtyping on-chip without cross-contamination. Though these
experiments were completed on several different microfluidic devices, these techniques could,
in principle, be combined into a single microfluidic device. This method resolves common
A1 and A2 subtypes with on-chip dilution and can use shear to distinguish rare, weakly
agglutinating A subtypes. Concentration-dependent agglutination of subtypes A1 and A2 is
believed to be the result of a difference in the number of antigens on the RBCs of each subtype.
While subtype A1 RBCs are believed to have antigens on both terminal and subterminal
complex sugars, subtype A2 RBCs are believed to have antigens on only subterminal sugars.
We found that rare, weakly agglutinating subtypes of type A RBCs can be distinguished from
type O RBCs by using shear rate. The weakly agglutinating type A RBCs are likely one of four
less common type A subtypes, such as A3,,Ax,,Am,and Ael, which cannot be distinguished from
type O blood by using the lectin DB dilution assay. We believe these results indicate that this
technology may be useful in reducing mistyping of these subtypes in the clinical setting. By
providing controlled shear, this system also enables acquisition of kinetic data on agglutination
to provide a quantitative description of the process. In our studies, shear rate was varied by
flow rates, but others have reported that shear rate could be tailored by creating devices with
more sophisticated geometries and applying them to studies of binding avidity of RBCs.32
Assuming that the techniques presented here can be successfully combined in a single device,
this plug-based method could be used to type blood for all 20 factors known to be present on
RBCs by including these factors in preformed antibody arrays. We routinely aspirate arrays of
48 different reagents separated by blank spacer plugs (buffer or gas) to screen many reaction
or protein crystallization conditions in a single experiment.14-16 Conversely, many blood
samples could be analyzed in the same experiment by aspirating all samples into a single array.
This array could be split into many identical arrays of smaller plugs, and each daughter array
could be combined with a different antibody.18 Also, by using the hybrid method17 with
automation and preformed antibody arrays, multiple antibodies at multiple concentrations
could be used to measure the binding avidity between RBCs and agglutinins all on a similar
style device. The hybrid approach may also be used to test the compatibility of the donor RBCs
with RBCs of perspective recipients with sickle cell anemia, where alloimmunization leads to
delayed transfusion reactions.33
Subtyping could be valuable in early detection of hemolytic disease of the newborn (HDN),
where the transfer of maternal IgG antibodies to the fetus through the placenta causes hemolysis
of fetal RBCs, currently performed with molecular-based applications.34 In HDN detection,
minimizing the necessary sample volume is important, and microfluidics provides reduced
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sample consumption in comparison to standard test tube subtyping methods. Reduced sample
consumption is also an important advance for point of care applications when volume is a
limiting factor. Assuming this system design works in a clinical setting, we believe point of
care applications could also benefit from the adaptation of this system to utilize Teflon tubing
instead of PDMS to enable bedside use.
In addition, automation of this system could enable rapid, complete blood typing and subtyping
in a single experiment using a single blood sample. While blood banks routinely automate
blood typing analysis of single samples, this platform could be extended to analyze multiple
samples in a serial fashion with no risk of cross-contamination (prevented by encapsulation of
all solutions within plugs), decreasing assay time. Incorporation of the hybrid method with
preformed cartridges of plugs would maintain automation while enabling concentration-
dependent antibody screening or cross-matching of blood samples.
This plug-based microfluidic agglutination assay is also capable of detecting bacteria. Bacterial
contamination of blood used in transfusions is a serious threat to patients with weakened
immune systems, and a combined assay that uses a cartridge of plugs containing antibodies to
determine the type of blood and also test for the presence of bacteria is an attractive long-term
opportunity provided by this microfluidic system. A dramatic improvement in sensitivity
would be required to detect 1–10 cfu/mL of bacteria by this method, and it remains to be seen
whether this or other microfluidic methods are most suitable for such detection. Plug-based
assays could also be extended to immunoassays for detection of viruses. Immunoassays are
known to be compatible with rapid-prototyping microfluidics.35 Similar to distinguishing
binding avidity of RBCs by using shear, plug-based microfluidics may be useful for detecting
changes in antibody avidity after virus infection as a function of shear.36-39 It remains to be
seen whether this technique can be extended beyond immunoassays to measure aggregation
of red blood cells in occlusive vascular diseases.40 We believe this plug-based platform could
become useful for a wide range of agglutination assays with minimal consumption of sample,
a high degree of multiplexing, and a high degree of control of interparticle interactions using
shear.
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Figure 1.
Plug-based microfluidic agglutination assay to distinguish type A from type B RBCs. (A) A
schematic drawing shows the device design used for the agglutination assay. (B, C) Time-lapse
bright-field microphotographs of representative plugs containing antibody, TRIS buffer, and
type A RBCs show that type A RBCs agglutinate in the presence of anti-A (B) but not in the
presence of anti-B (C). (D) A graph quantifies the change in contrast of plugs, indicative of
agglutination, of type A RBCs exposed to anti-A (blue squares) or anti-B (red circles) (n = 3
plugs). Contrast analysis was performed by using ImageJ. Arrows indicate the direction of
fluid flow.
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Figure 2.
ABO and D blood typing in a single experiment by using a preformed antibody array coupled
to a microfluidic device. (A) A schematic drawing illustrates the antibody array that was used
for ABO and D blood typing (gas = air, buff = TRIS buffer; D = anti-D; A = anti-A; B = anti-
B). (B) A schematic drawing illustrates merging of plugs in the antibody array with a solution
of RBCs. (C) A schematic drawing and bright-field microphotographs show that merging a
3% solution of type A+ RBCs with the antibody array resulted in agglutination in plugs of anti-
D or anti-A merged with RBCs, but not in plugs of anti-B merged with RBCs. Arrows indicate
the direction of fluid flow.
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Figure 3.
Microfluidic subtyping of type A RBCs by on-chip dilution of lectin from D. biflorus (DB).
(A) A schematic drawing shows the microfluidic device used for subtyping. Flow rate of lectin
DB and buffer were varied to achieve low and high lectin DB concentrations, while the flow
rate of RBCs and the carrier fluid remained constant. (B) Low lectin DB concentration (0.09
mg/mL) did not agglutinate subtype A2B+ RBCs, because plugs were dark and uniform in
color, indicating no agglutination. (C) High lectin DB concentration (0.72 mg/mL) resulted in
agglutination of subtype A2B+ RBCs, as expected for RBCs of subtype A2. Images in panels
B and C correspond to red (solid circles) and blue (hollow circles) data points in panel E,
respectively. (D) Type A+ RBCs agglutinate at both low and high lectin DB concentrations
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(images at low concentration of lectin DB not shown), indicating that these RBCs were subtype
A1. Images in panel D correspond to green (hollow) data points in panel F. (E) Contrast
variation in plugs containing subtype A2B+ RBCs at low (red solid circles) and high (blue
hollow circles) lectin DB concentration quantitatively show the presence of agglutinins over
time. (F) Contrast variation in plugs containing type A+ RBCs of unknown subtype at low
(black solid squares) and high (green hollow squares) lectin DB concentration quantitatively
show the presence of agglutinins over time. In panels E and F, n = 3 plugs. Arrows indicate
the direction of flow.
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Figure 4.
Binding avidity of type A RBCs distinguished by using shear in plug-based microfluidics. (A)
A schematic drawing shows the device used to characterize the binding avidity of type A RBCs
by using shear, and the enlarged inset shows the winding, bumpy channels included to promote
mixing. (B, C) Type A RBCs with strong binding avidity agglutinate at a shear rate of 13 s-1
(B), while type A RBCs with weak binding avidity do not agglutinate (C). (D, E) When the
shear rate was reduced from 13 to 0 s-1, RBCs with strong binding avidity remained
agglutinated (D), and those with weak binding avidity agglutinated (F). (E, G) When the shear
rate was increased to 530 s-1, RBCs with strong binding avidity remained agglutinated (E),
while agglutinins from RBCs with weak binding avidity broke up (G). (H, I) Contrast analysis
of plugs at shear rates of 0 (blue squares), 13, (red circles), and 530 s-1 (black triangles) indicates
that agglutination of type A RBCs with strong binding avidity is independent of shear rate (H),
while agglutination of type A RBCs with weak binding avidity is affected by shear rate (I). A
decrease in contrast within plugs correlates with the breakup of agglutinins (n = 2 plugs in all
data points). Symbols in panels B—G correspond to symbols in panels H and I. Note the
difference in scale of the Y-axis in graphs H and I.
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Figure 5.
Plug-based microfluidic agglutination assays for the detection of S. aureus. (A) A schematic
drawing shows the device used in the agglutination assay to detect bacteria. (B) Time-lapse
microphotographs show that agglutination in the presence of bacteria begins in as little as 20
s. (C) Time-lapse microphotographs of a control plug with no bacteria shows that latex beads
alone do not cause agglutination. (D) Contrast analysis of plugs with (red squares) and without
(blue circles) bacteria quantitatively shows agglutination over time (n = 3 plugs). Arrows
indicate the direction of flow.
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